523 related articles for article (PubMed ID: 36335396)
21. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
22. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
24. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape.
Xie D; Jin X; Sun R; Zhang M; Lu W; Cao X; Guo R; Zhang Y; Zhao M
Transl Oncol; 2023 Aug; 34():101695. PubMed ID: 37224766
[TBL] [Abstract][Full Text] [Related]
25. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
26. A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of Vγ9Vδ2 T cells.
Zhang X; Ang WX; Du Z; Ng YY; Zha S; Chen C; Xiao L; Ng JY; Chng WJ; Wang S
Immunotherapy; 2022 Apr; 14(5):321-336. PubMed ID: 35152722
[No Abstract] [Full Text] [Related]
27. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
28. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
[TBL] [Abstract][Full Text] [Related]
29. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S
J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669
[TBL] [Abstract][Full Text] [Related]
30. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
31. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.
Dong H; Ham JD; Hu G; Xie G; Vergara J; Liang Y; Ali A; Tarannum M; Donner H; Baginska J; Abdulhamid Y; Dinh K; Soiffer RJ; Ritz J; Glimcher LH; Chen J; Romee R
Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2122379119. PubMed ID: 35696582
[TBL] [Abstract][Full Text] [Related]
32. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
33. Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies.
Asadi M; Kiani R; Razban V; Faraji SN; Ahmadi A; Fallahi J; Ramezani A; Erfani N
Iran J Immunol; 2023 Dec; 20(4):410-426. PubMed ID: 38102941
[TBL] [Abstract][Full Text] [Related]
34. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Gurney M; Stikvoort A; Nolan E; Kirkham-McCarthy L; Khoruzhenko S; Shivakumar R; Zweegman S; Van de Donk NWCJ; Mutis T; Szegezdi E; Sarkar S; O'Dwyer M
Haematologica; 2022 Feb; 107(2):437-445. PubMed ID: 33375774
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
[TBL] [Abstract][Full Text] [Related]
36. Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Gauthier L; Virone-Oddos A; Beninga J; Rossi B; Nicolazzi C; Amara C; Blanchard-Alvarez A; Gourdin N; Courta J; Basset A; Agnel M; Guillot F; Grondin G; Bonnevaux H; Bauchet AL; Morel A; Morel Y; Chiron M; Vivier E
Nat Biotechnol; 2023 Sep; 41(9):1296-1306. PubMed ID: 36635380
[TBL] [Abstract][Full Text] [Related]
37. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
39. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
40. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
